<DOC>
	<DOCNO>NCT02562313</DOCNO>
	<brief_summary>This study constitute 2 part : Part A : A total 36 patient enrolled part A . Each eligible subject participate two 14-day treatment period Continuous Subcutaneous Insulin Infusion ( CSII ) BioChaperone insulin lispro insulin lispro ( Humalog® , Eli Lilly Company ) . Each treatment period consist 10 treatment day free living condition ( e.g . home / workplace ) standardise condition clinic . Various assessment pharmacodynamics , pharmacokinetics , pump compatibility , short-term efficacy safety perform selected day , include : - Mixed Meal Test ( MMT ) , Day 1 , Day 3 , Day 12 Day 14 , assess post-prandial glucose response 6 hour individualized standard meal ( fix nutrient ratio ) ingestion bolus administration via CSII . - Continuous Glucose Monitoring ( CGM ) , ( Day 1 - 14 ) use blind mode ( i.e . neither subject investigator aware sensor glucose value ) . - Pump compatibility ( Day 1 - 14 ) : Subjects continue CSII treatment Investigational Medicinal Products ( IMP ) outpatient period . Part B : A total 44 patient enrol . Subjects randomize 4-period cross-over study aim compare performance BC Lispro Humalog prandial bolus administration two different CSII system ( Roche Accu-Chek® Spirit Medtronic Paradigm® Veo™ ) syringe . Pharmacodynamics , pharmacokinetics , pump compatibility safety analyze . Each period include mixed meal tolerance test CSII device mix meal tolerance test dose insulin administer syringe .</brief_summary>
	<brief_title>A Trial Investigating Continuous Subcutaneous Insulin Infusion Liquid Formulation BioChaperone Insulin Lispro Comparison Humalog®</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<criteria>Type 1 diabetes least 12 month Body Mass Index ( BMI ) 18.5 28.5 kg/m^2 , inclusive Using use Roche CSII system ( AccuChek® Spirit Combo/ Accu Chek® Spirit ) least 6 month screen . In Part B subject use form CSII treatment least 6 month screen include . HbA1c &lt; = 9.0 % . Total insulin dose &lt; 1.2 ( I ) U/kg/day Ability calculate insulin bolus manually use bolus calculator willingness consume regular meal , perform carbohydrate counting , selfmonitoring plasma glucose ( SMPG ) profile use Continuous Glucose Monitoring ( CGM ) . Fasting Cpeptide &lt; = 0.30 nmol/L Known suspected hypersensitivity Investigational Medicinal Product ( ) ( IMP ( ) ) relate product Type 2 diabetes mellitus Previous participation trial . Receipt investigational product clinical trial within 60 day randomisation trial Clinically significant abnormal haematology , biochemistry , urinalysis , coagulation screen test Presence clinically significant acute gastrointestinal symptom Known slow gastric empty gastrointestinal surgery Unusual meal habit special dietary requirement unwillingness eat food provide trial History diabetic ketoacidosis ( DKA ) episodes require hospitalization within 6 month prior screen History abscess infusion site within 6 month prior screen Hypoglycaemia unawareness judge Investigator History severe hypoglycaemic episode require hospitalization within last 6 month prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>